Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
← catalyst calendarNCT05485831 · readout ≤ 193 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Advice Pharma Group srl.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
111actual
Sites
18
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-24 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lennox Gastaut Syndrome
- Dravet Syndrome
- Tuberous Sclerosis Complex
Intervention
- Drug: Epidiolex 100 mg/mL Oral Solution
Primary outcome
what the primary-completion date above is the date OFNumber of Participants Remaining on Therapy from Enrollment
measured Baseline up to Week 52 post-dose.
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed